Biocryst Pharmaceuticals buy Royal Bank of Canada
Start price
06.05.25
/
50%
€8.90
Target price
06.05.26
€11.51
Performance (%)
-14.16%
Price
01.07.25
€7.64
Summary
This prediction is currently active. The prediction for Biocryst Pharmaceuticals disappoints with a performance of -14.16%. This prediction currently runs until 06.05.26. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biocryst Pharmaceuticals | -10.646% | -10.646% |
| iShares Core DAX® | -0.081% | -1.435% |
| iShares Nasdaq 100 | -0.201% | 1.543% |
| iShares Nikkei 225® | 1.465% | 1.838% |
| iShares S&P 500 | 0.215% | 1.237% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $13.00 price target on the stock, up previously from $11.00.
Ratings data for BCRX provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€7.60
30.06.25
30.06.25
€11.09
30.06.26
30.06.26
0.47%
01.07.25
01.07.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€5.91
11.04.25
11.04.25
€9.75
11.04.26
11.04.26
29.24%
01.07.25
01.07.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€7.79
25.02.25
25.02.25
€10.47
25.02.26
25.02.26
-1.93%
01.07.25
01.07.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€6.61
05.11.24
05.11.24
€9.16
05.11.25
05.11.25
15.55%
01.07.25
01.07.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€6.95
25.09.23
25.09.23
€9.44
25.09.24
25.09.24
-2.42%
26.09.24
26.09.24